drugset
Drugs / Covigenix VAX-001
last change Dec 2023 re-read 3 minutes ago

Covigenix VAX-001

Vaccine

Developed for
COVID-19
Investigated by
Aegis Life, Inc. · Canadian Institutes of Health Research (CIHR) · Centre national de recherche et de formation sur le paludisme · Clinical Pharma Solutions Inc · Entos Pharmaceuticals Inc.

Trials 1

today NCT04591184 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04591184 Apr 2021 → Dec 2023 COVID-19 Entos Pharmaceuticals Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Covigenix VAX-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04591184 ↗
Modality Vaccine “Covigenix VAX-001 is a novel plasmid DNA-based vaccine” NCT04591184 ↗
Route Intramuscular “Participants will receive an intramuscular (IM) injection” NCT04591184 ↗